



## Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

November 4, 2015

DUBLIN, Nov. 4, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at three upcoming investor conferences.

- 24th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Wednesday, November 11, 2015 at 11:00 a.m. EST / 4:00 p.m. GMT. Russell Cox, executive vice president and chief operating officer, will provide an overview of the company and a business and financial update.
- Jefferies Autumn 2015 Global Healthcare Conference in London, England on Thursday, November 19, 2015 at 10:40 a.m. GMT / 5:40 a.m. EST. Iain McGill, senior vice president, Jazz Pharmaceuticals Europe and rest of world, will provide an overview of the company and a business and financial update.
- Piper Jaffray 27th Annual Healthcare Conference in New York, NY on Tuesday, December 1, 2015 at 9:00 a.m. EST / 2:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.

A live audio webcast of each presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast of each presentation will be available for at least one week following the presentation on the Investors & Media section of the company's website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

### About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase *Erwinia chrysanthemi*) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).



Logo - <http://photos.prnewswire.com/prnh/20150930/272253LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-in-three-upcoming-investor-conferences-300172548.html>

SOURCE Jazz Pharmaceuticals plc

Investors: Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717; Media: Laurie Hurley, Vice President, Corporate Affairs, Ireland, +353 1 634 7894, U.S., +1 650 496 2796